NEW YORK, NY / ACCESSWIRE / October 13, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Fastly, Inc. (NYSE:FSLY)
CONTACT JAKUBOWITZ ABOUT FSLY:
https://claimyourloss.com/securities/fastly-inc-loss-submission-form/?id=10056&from=1
Class Period : May 6, 2020 - August 5, 2020
Lead Plaintiff Deadline : October 26, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Fastly’s largest customer was ByteDance, operator of TikTok, which was known to have serious security risks and was under intense scrutiny by U.S. officials; (2) there was a material risk that Fastly’s business would be adversely impacted should any adverse actions be taken against ByteDance or TikTok by the U.S. government; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
CONTACT JAKUBOWITZ ABOUT BMRN:
https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=10056&from=1
Class Period : February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline : November 24, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Royal Caribbean Cruises Ltd. (NYSE:RCL)
CONTACT JAKUBOWITZ ABOUT RCL:
https://claimyourloss.com/securities/royal-caribbean-cruises-ltd-loss-submission-form/?id=10056&from=1
Class Period : February 4, 2020 - March 17, 2020
Lead Plaintiff Deadline : December 7, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law